FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models
Authors:
- X.-C. KongXKX.-C. Kong
- C. QianCQC. Qian
- D. ZhangDZD. Zhang
- 1 January 2012
- journal article
- Published by Elsevier in Neuroscience
- Vol. 202, 396-404
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation of China (81000568, 81001430)
- Chinese National Basic Research Program (973 program (2007CB507400)
This publication has 33 references indexed in Scilit:
- DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathwayProceedings of the National Academy of Sciences, 2010
- Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative diseasePharmacology & Therapeutics, 2007
- The Akt–GSK-3 signaling cascade in the actions of dopamineTrends in Pharmacological Sciences, 2007
- The Two TORCs and AktDevelopmental Cell, 2007
- Protocol for the MPTP mouse model of Parkinson's diseaseNature Protocols, 2007
- Neuronal macroautophagy: From development to degenerationMolecular Aspects of Medicine, 2006
- Pharmacological Study of the Novel Compound FLZ Against Experimental Parkinson's Models and Its Active MechanismMolecular Neurobiology, 2005
- Parkinson's DiseaseNeuron, 2003
- Description of Parkinson's Disease as a Clinical SyndromeAnnals of the New York Academy of Sciences, 2003
- Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR ActionCell, 2002